Michal Segal

First-line pembrolizumab and trastuzumab in HER2-positive oesophageal, gastric, or gastro-oesophageal junction cancer: an open-label, single-arm, phase 2 trial

Yelena Y. Janjigian, Steven B. Maron, Walid K. Chatila et al. · The Lancet Oncology · 2020 · 357 citations · Full text

Medicine, Oncology, Pharmacotherapy +16

Phase 1 trial evaluating cisplatin, gemcitabine, and veliparib in 2 patient cohorts: Germline <i>BRCA</i> mutation carriers and wild‐type <i>BRCA</i> pancreatic ductal adenocarcinoma

Eileen M. O’Reilly, Jonathan W. Lee, Maeve A. Lowery et al. · Cancer · 2018 · 103 citations

Medicine, Oncology, Pharmacology +12

Leucovorin plus 5-fluorouracil: an effective treatment for metastatic colon cancer.

Leslie R. Laufman, K A Krzeczowski, Ralph W. Roach et al. · Journal of Clinical Oncology · 1987 · 71 citations

Medicine, Oncology, Pharmacology +15

A phase 2 study of the insulin‐like growth factor‐1 receptor inhibitor MK‐0646 in patients with metastatic, well‐differentiated neuroendocrine tumors

Diane Reidy‐Lagunes, Efsevia Vakiani, Michal Segal et al. · Cancer · 2012 · 65 citations

Medicine, Oncology, Pharmacology +13

Monthly docetaxel and weekly gemcitabine in metastatic breast cancer: A phase II trial

Leslie R. Laufman, C. Harris Spiridonidis, Jessica Pritchard et al. · Annals of Oncology · 2001 · 53 citations · Full text

Medicine, Oncology, Pharmacology +17